Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: An EORTC phase III study (10863)

L. Beex, Carsten Rose, H. Mouridsen, J. Jassem, M. Nooij, J. Estape, R. Paridaens, M. Piccart, T. Gorlia, S. Lardenoije, L. Baila

Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

Fingeravtryck

Fördjupa i forskningsämnen för ”Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: An EORTC phase III study (10863)”. Tillsammans bildar de ett unikt fingeravtryck.

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science